Clinical pharmacology of bimatoprost

Bibliography

• American Academy of Ophthalmology Preferred Practice Pattern™: Primary Open-Angle Glaucoma. (2000).
   Google Scholar
• QUIGLEY HA: Number of people with glaucoma worldwide. Br. J. Ophthalmol. (1996) 80:389–393.
   PubMed Web of Science ®Google Scholar
• THYLEFORS B, NEGREL AD: The global impact of glaucoma. Bull. World Health Org. (1994) 72:323–326.
   PubMed Web of Science ®Google Scholar
• PALMBERG P: Answers from the ocular hypertension treatment study. Arch. Ophthalmol. (2002) 120:829–830.
   PubMed Web of Science ®Google Scholar
• SINGH K, SPAETH G, ZIMMERMAN T, MINCKLER D: Target pressure — glaucomatologists’ holy grail. Ophthalmol. (2000) 107:629–630.
   PubMed Web of Science ®Google Scholar
• ZEYEN T: Target pressures in glaucoma. Bull. Soc. Belge. Ophthalmol. (1999) 274:61–65.
   PubMedGoogle Scholar
• LIU JH, KRIPKE DF, TWA MD et al. : Twenty-four-hour pattern of intraocular pressure in the ageing population. Invest. Ophthalmol. Vis. Sci. (1999) 40:2912–2917.
   PubMed Web of Science ®Google Scholar
• DAVID R, ZANGWILL L, BRISCOE D, DAGAN M, YAGEV R, YASSUR Y: Diurnal intraocular pressure variations: an analysis of 690 diurnal curves. Br. J. Ophthalmol. (1992) 76:280–283.
   PubMed Web of Science ®Google Scholar
• ZEIMER RC, WILENSKY JT, GIESER DK: Presence and rapid decline of early morning intraocular pressure peaks in glaucoma patients. Ophthalmol. (1990) 97:547–550.
   PubMed Web of Science ®Google Scholar
• SACCA SC, ROLANDO M, MARLETTA A et al.: Fluctuations of intraocular pressure during the day in open-angle glaucoma, normal-tension glaucoma and normal subjects. Ophthalmologica. (1998) 212:115–119.
   Web of Science ®Google Scholar
• ASRANI S, ZEIMER R, WILENSKY J, GIESER D, VITALE S, LINDENMUTH K: Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J. Glaucoma (2000) 9:134–142.
   PubMed Web of Science ®Google Scholar
• GRANT WM: Clinical measurements of aqueous outflow. AMA Arch. Ophthalmol. (1951) 46:113–131.
   PubMed Web of Science ®Google Scholar
• BECKER B: Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J. Glaucoma (2000) 9:487–488.
   PubMed Web of Science ®Google Scholar
• BRUBAKER RF, SCHOFF EO, NAU CB et al. : Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am. J. Ophthalmol. (2001) 131:19–24.
   PubMed Web of Science ®Google Scholar
• BRUBAKER RF: Mechanism of action of bimatoprost (Lumigan). Surv. Ophthalmol. (2001) 45(Suppl. 4): S347–S351.
   Google Scholar
• DIGGORY P, FRANKS W: Medical treatment of glaucoma — a reappraisal of the risks. Br. J. Ophthalmol. (1996) 80:85–89.
   PubMed Web of Science ®Google Scholar
• WOODWARD DF, KRAUSS AH-P, CHEN J et al.: Pharmacological characterization of a novel antiglaucoma agent. J. Pharmacol. Exp. Ther. (2003) 305:772–785.
   PubMed Web of Science ®Google Scholar
• KRAUSS H P, WOODWARD DF: Update on the mechanism of action of bimatoprost: a review and discussion of new evidence. Surv. Ophthalmol. (2004) 49(Suppl. 1): S5–S11.
   Google Scholar
• CHRISTIANSEN GA, NAU CB, MCLAREN JW, JOHNSON DH: Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma. Ophthalmol. (2004) 111(9):1658–1662.
   PubMed Web of Science ®Google Scholar
• WOODWARD DF, KRAUSS AH-P, CHEN J et al.: The pharmacology of bimatoprost (Lumigan™). Surv. Ophthalmol. (2001) 45(Suppl. 4): S337–S345.
   Google Scholar
• SHARIF NA, WILLIAMS GW, KELLY CR: Bimatoprost and its free acid are prostaglandin FP receptor agonists. Eur. J. Pharmacol. (2001) 432:211–213.
   PubMed Web of Science ®Google Scholar
• CHEN J, SENIOR J, MARSHALL K et al.: Studies using isolated uterine and other preparations show bimatoprost and prostanoid FP agonists have different activity profiles. Br. J. Pharmacol. (2005) 144:493–501.
   PubMed Web of Science ®Google Scholar
• SPADA CS, KRAUSS AH-P, WOODWARD DF et al. : Bimatoprost and prostaglandin F2α selectively stimulate intracellular calcium signalling in different cat iris sphincter cells. Exp. Eye Res. (2005) 80:135–145.
   PubMed Web of Science ®Google Scholar
• WOODWARD DF, PHELPS RL, KRAUSS AH et al. : Bimatoprost: a novel antiglaucoma agent. Cardiovasc. Drug Rev. (2004) 22(2):103–120.
   PubMed Web of Science ®Google Scholar
• MATIAS I, CHEN J, DE PETROCELLIS L et al.: Prostaglandin ethanolamides (prostamides): in vitro pharmacology and metabolism. J. Pharmacol. Exp. Ther. (2004) 309:745–757.
   PubMed Web of Science ®Google Scholar
• LIANG Y, LI C, GUZMAN VM et al. : Comparison of prostaglandin F2α’ bimatoprost (prostamide), and butaprost (EP2 agonist) on Cyr61 and connective tissue growth factor gene expression. J. Biol. Chem. (2003) 278:27267–27277.
   PubMed Web of Science ®Google Scholar
• LIANG Y, LI C, GUZMAN VM et al. : Upregulation of orphan nuclear receptor Nur77 following PGF2α’ bimatoprost, and butaprost treatments. Essential role of a protein kinase C pathway involved in EP2 receptor activated Nur77 gene transcription. Br. J. Pharmacol. (2004) 142:737–748.
   PubMed Web of Science ®Google Scholar
• WANG R-F, SERLE JB, GAGLIUSO D, MITTAG TW, PODOS TW: Effect of latanoprost (L) or bimatoprost (B) alone and in combination on intraocular pressure (IOP) in glaucomatous monkey eyes. Annual Meeting of the Association for Research in Vision and Ophthalmology. Fort Lauderdale, FL, USA (2002).
   Google Scholar
• GAGLIUSO DJ, WANG RF, MITTAG TW, PODOS SM: Additivity of bimatoprost or travoprost to latanoprost in glaucomatous monkey eyes. Arch. Ophthalmol. (2004) 122(9):1342–1347.
   PubMed Web of Science ®Google Scholar
• HERNDON LW, ASRANI SG, WILLIAMS GH, CHALLA P, LEE PP: Paradoxical intraocular pressure elevation after combined therapy with latanoprost and bimatoprost. Arch Ophthalmol. (2002) 120(6):847–849.
   PubMed Web of Science ®Google Scholar
• GANDOLFI SA, CIMINO L: Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost. Ophthalmol. (2003) 110:609–614.
   PubMed Web of Science ®Google Scholar
• BOURNIAS TE, LEE D, GROSS R, MATTOX C: Ocular hypotensive efficacy of bimatoprost when used as a replacement for latanoprost in the treatment of glaucoma and ocular hypertension. Ocul. Pharmacol. Ther. (2003) 19:193–203.
   PubMed Web of Science ®Google Scholar
• WILLIAMS RD: Efficacy of bimatoprost in glaucoma and ocular hypertension unresponsive to latanoprost. Adv. Ther. (2002) 19:275–281.
   PubMed Web of Science ®Google Scholar
• CHEN J, WOODWARD DF: Lumigan®: a novel drug for glaucoma therapy. Optom. In Pract. (2002) 3:95–102.
   Google Scholar
• DAHLIN DC, BERGAMINI MV, CURTIS MA, DEAN TR, KIEHLBAUCH CC, CHASTAIN JE: Bimatoprost hydrolysis to 17–phenyl PGF2α by rabbit and monkey ocular tissues, in vivo. Annual Meeting of the Association for Research in Vision and Ophthalmology. Fort Lauderdale, FL, USA (2002).
   Google Scholar
• SHARIF NA, KE TL, HAGGARD K et al.: Bimatoprost hydrolysis to 17–phenyl PGF2α by human and rabbit ocular tissues and agonist activity of bimatoprost and 17–phenyl PGF22α. Annual Meeting of the Association for Research in Vision and Ophthalmology. Fort Lauderdale, FL, USA (2002).
   Google Scholar
• CAMRAS CB, TORIS CB, SJOQUIST B et al.: Detection of the free acid of bimatoprost in aqueous humor samples from human eyes treated with bimatoprost before cataract surgery. Ophthalmol. (2004) 111(12):2193–2198.
   PubMed Web of Science ®Google Scholar
• DAHLIN DC, CRAVEN ER, MOSTER M et al.: Human aqueous humor concentrations of bimatoprost and bimatoprost free acid following topical ocular dosing of Lumigan (bimatoprost (17—phenyl-trinor-PGF2α) 0.03% ophthalmic solution). Invest. Ophthalmol. Vis. Sci. (2004) 45:A2096.
   Web of Science ®Google Scholar
• CANTOR LB, HOOP J, WUDUNN D et al.: Determination of bimatoprost hydrolysis in the aqueous humor of cataract patients. Invest. Ophthalmol. Vis. Sci. (2004) 45:A3956.
   Web of Science ®Google Scholar
• SJÖQUIST B, STJERNSCHANTZ J: Ocular and systemic pharmacokinetics of latanoprost in humans. Surv. Ophthalmol. (2002) 47(Suppl. 1): S6–S12.
   Google Scholar
• CHEETHAM JK, TANG-LIU D, YU Z et al.: Long-term systemic exposure of Lumigan in patients with glaucoma or ocular hypertension. Annual Meeting of the Association for Research in Vision and Ophthalmology. Fort Lauderdale, FL, USA (2002).
   Google Scholar
• SHERWOOD M, BRANDT J: For the Bimatoprost Study Groups 1 ’ 2. 6-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated IOP. Surv. Ophthalmol. (2001) 45(Suppl. 4): S361–S368.
   Google Scholar
• NOECKER RJ, DIRKS MS, CHOPLIN NT et al. : A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am. J. Ophthalmol. (2003) 135:55–63.
   PubMed Web of Science ®Google Scholar
• GANDOLFI S, SIMMONS ST, STURM R, CHEN K, VANDENBURGH AM, THE BIMATOPROST STUDY GROUP 3: Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv. Ther. (2001) 18:110–121.
   PubMed Web of Science ®Google Scholar
• HIGGINBOTHAM EJ, SCHUMAN JS, GOLDBERG I et al.: One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch. Ophthalmol. (2002) 120:1286–1293.
   PubMed Web of Science ®Google Scholar
• DUBINER H, COOKE D, DIRKS M, STEWART WC, VANDENBURGH AM, FELIX C: Efficacy and safety of bimatoprost in patients with elevated IOP: a 30-day comparison with latanoprost. Surv. Ophthalmol. (2001) 45(Suppl. 4): S353–S360.
   Google Scholar
• PARRISH RK, PALMBERG P, SHEU W-P, FOR THE XLT STUDY GROUP: A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am. J. Ophthalmol. (2003) 135:688–703.
   PubMed Web of Science ®Google Scholar
• COLEMAN AL, LERNER F, BERNSTEIN P, WHITCUP SM: A 3-month randomized controlled trial of bimatoprost (Lumigan®) versus combined timolol and dorzolamide (Cosopt®) in patients with glaucoma or ocular hypertension. Ophthalmol. (2003) 110:2362–2368.
   PubMed Web of Science ®Google Scholar
• CANTOR LB: Bimatoprost: a member of a new class of agents, the prostamides, for glaucoma management. Expert Opin. Investig. Drugs (2001) 10:721–731.
   PubMed Web of Science ®Google Scholar
• WALTERS TR, DUBINER HB, CARPENTER S et al.: 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial. Surv. Ophthalmol. (2004) 49:S26–S35.
   PubMed Web of Science ®Google Scholar
• COHEN JS, GROSS RL, CHEETHAM JK et al. : Two-year doublemasked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension. Surv. Ophthalmol. (2004) 49:S45–S52.
   PubMed Web of Science ®Google Scholar
• WHITCUP SM, CANTOR LB, VANDENBURGH AM, CHEN K: A randomised, double-masked, multi-centre clinical trial comparing bimatoprost and timolol for the treatment of glaucoma and ocular hypertension. Br. J. Ophthalmol. (2003) 87(1):57–62.
   PubMed Web of Science ®Google Scholar
• NOECKER RJ, EARL ML, MUNDORF T et al.: Bimatoprost 0.03% versus travoprost 0.004% in black Americans with glaucoma or ocular hypertension. Adv. Ther. (2003) 20:121–128.
   PubMed Web of Science ®Google Scholar
• CANTOR LB, WUDUNN D, CORTES A et al.: Ocular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension. Surv. Ophthalmol. (2004) 49:S12–S18.
   PubMed Web of Science ®Google Scholar
• MELAMED S, BOSSAWSKA I, LAROCH C, BIMATOPROST ADJUNCTIVE TO TIMOLOL STUDY GROUP: Effectiveness of bimatoprost (Lumigan®) as adjunctive therapy with topical beta-blockers in patients with glaucoma or ocular hypertension: a 3-month, multi-center, double-masked, randomized, vehicle-controlled trial with double-masked extension of bimatoprost treatment to 1 year. Annual Meeting of the Association for Research in Vision and Ophthalmology. Fort Lauderdale, FL, USA (2002).
   Google Scholar
• LEE DA, GROSS R, MUNDORF TK: Efficacy and safety of bimatoprost 0.03% (Lumigan) in a large-scale, open-label clinical trial. Invest. Ophthalmol. Vis. Sci. (2002) 43:A4105.
   Web of Science ®Google Scholar
• SCHERER WJ: A retrospective review of non-responders to latanoprost. J. Ocul. Pharmacol. Ther. (2002) 18:287–291.
   PubMed Web of Science ®Google Scholar